Smolen JS, et al. - Researchers sought to identify factors that could predict an insufficient response to methotrexate in patients with early rheumatoid arthritis (RA). In this post hoc analysis of the OPTIMA and PREMIER studies, they found response to methotrexate treatment and radiographic progression at 6 months could be predicted by baseline disease characteristics and early disease activity in patients with early RA. Findings suggested a relationship between the addition of adalimumab at 6 months after methotrexate failure and improved outcomes. In patients with early RA, treatment-to-target strategies and timely adaptation of therapy were supported in the findings.